Ohr Pharmaceutical to Announce Fiscal Third Quarter 2017 Results on August 8

NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. OHRP, a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its third fiscal quarter ended June 30, 2017 after the market close on Tuesday, August 8, 2017.  The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.

About Ohr Pharmaceutical, Inc. 
Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com. 

Contact:
Ohr Pharmaceutical Inc.                                 
Investor Relations                                           
888-388-2327                                                  
ir@ohrpharmaceutical.com       

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com